The Future of Disease Detection

Leadership

Guy LaTorre, Chief Executive Officer

Mr. LaTorre brings over 25 years of experience in the development and commercialization of medical devices and consumer products in a startup company environment. Guy was a co-founder and Vice President of Business Development at Novamin Technology Inc. where he was responsible for identifying and managing the Company’s relationships with its key clients in the dental products field, including product development of in-office and at-home use products using the company’s proprietary ingredient. In that role, he formed and managed product development partnerships between NTI and the leading marketers of professional dental products, including Dentsply Corp, 3M Corp, Sultan Healthcare, Sunstar and others until the company was sold to GlaxoSmithKline (GSK) in 2010 for USD $135 million.

Previously, Guy was the Director of Scientific Affairs at USBiomaterials Corp. which developed and sold synthetic bone grafting products for use in dental, head, neck and orthopedic surgeries. His responsibilities also included product development, manufacturing and business development activities. Prior to USBiomaterials, Guy was the Laboratory Manager of the University of Florida Advanced Materials Research Center where he was responsible for the managed transfer of licensed university technologies to private startup companies. Guy has been author or co-author of over fifty scientific publications and holds seven US patents with associated filings worldwide.

 


kal

Kal Malhi, President and Director

Mr. Malhi is a Canadian entrepreneur and businessman. He is a retired member of the Royal Canadian Mounted Police and also President of BullRun Group, a private investment company specializing in early stage business development.

His interest in issues of individual rights aligned with public safety through law enforcement initiatives shaped his vision in the founding of Cannabix Breathalyzer, Inc where Mr. Malhi was instrumental in growing the company from a startup to a publicly traded company with a valuation in excess of $30 million dollars.

This successful enterprise broadened his interest in breath analysis and the extraordinary opportunities in the sector. His extensive network of contacts and personal relationships has enabled him to assemble a growing team aimed at unearthing the potential for commercial breath analysis applications as a new and potentially high growth sector


raj

Raj Attariwala, MD, PhD., Lead Engineer

Dr. Attariwala is a dual board certified Radiologist and Nuclear Medicine physician certified in both Canada and the United States. He received his formal medical training at University of British Columbia with periods of specialized medical training at Memorial Sloan Kettering Cancer Centre (New York), UCLA and USC. He holds a doctorate in Biomedical Engineering from Northwestern University (Evanston, IL).

Dr. Attariwala is a practicing physician in British Columbia and owner of AIM medical imaging. He has pioneered advances in the field of whole body medical imaging and authored numerous publications and presented at international medical conferences on whole body imaging and cancer detection.

Dr. Attariwala has extensively investigated breath testing applications and efficacy in a related role at Cannabix Technologies Inc. where he developed a breath testing system for drug impairment.


yost

Richard A. Yost Ph.D., Scientific Advisor

Dr. Yost, Col. Allen R. & Margaret G. Crow Professor and Head of Analytical Chemistry at the University of Florida received his B.S. degree in Chemistry from the University of Arizona in 1974. In 1975 he pursued an NSF graduate fellowship at Michigan State University focusing on electronics and computerized instrumentation. He received his Ph.D. in 1979 and assumed the position of Assistant Professor at the University of Florida and went on to become head of the Analytical Chemistry Division.

Dr. Yost’s research has involved over 100 graduate students funded by over $40 million in research grants, and has published over 160 papers and 16 patents. Over $30 billion worth of instruments have been sold based on these patents.

He serves as a member of the Florida Board of Governors (Regents) and as the Chair of the Advisory Council of Faculty Senates of Florida. He is past Chair of the UF Faculty Senate and served on the UF Board of Trustees. He served as Treasurer and Secretary of the American Society for Mass Spectrometry, and on the editorial boards of The Journal of the American Society for Mass Spectrometry and The International Journal of Mass Spectrometry.


Prof. Hossam Haick, Consultant

Dr. Haick is a full Professor in Chemical Engineering and Nanotechnology at the Technion Israel Institute of Technology and an expert in the field of nanotechnology and non-invasive disease diagnosis.  Dr. Haick is the recipient of the prestigious Marie Curie Excellence Award, ERC Award, and the FP-7 and Horizon 2020 consortium Awards. He is also the recipient of more than 56 international honors and prizes for his achievements. Prof. Haick has published over 170 articles and serves on the editorial board of several peer-reviewed journals, and is a senior scientific advisory member of several national and international companies and institutes. Prof. Haick’s ground-breaking research has led to the development of the NA-NOSE nanotechnology-based breath test technology for detecting biomarkers of disease. Certain disease conditions produce chemicals called volatile organic compounds (VOCs), which easily evaporate into the air and produce a discernible scent profile. The Na-NOSE chip detects the unique “signature” of VOCs in exhaled breath. As a consultant to Breathtec, Prof. Haick will guide the company’s development of the NA-NOSE disease detection system and design the clinical trials to be undertaken by the company.


michael

Michael T. Costanzo, Ph.D., Chief Technical Officer

Dr. Costanzo enjoys a passion for science that has directed his career path firmly into the field of analytical chemistry. Over the past five years he has investigated a variety of advanced experimental methodologies and instrumentation with the Yost Research Group at the University of Florida. During this period he utilized UV spectroscopy to help in standardizing procedures for manufacturing respiratory medications, employed novel ion mobility spectrometric techniques and devices to analyze exhaled breath, and performed multiple metabolomics studies of melanoma. Through his efforts, he acquired a vast knowledge of analytical techniques and methodologies and an immense desire for scientific progress.

Previously, Costanzo obtained his Bachelor of Science in chemistry at the State University of New York (Buffalo). During this period he conducted research under Dr. Troy Wood utilizing mass spectrometry to examine products of enzymatic protein digestion in the interest of studying metabolic markers of autism in children. Upon graduation in 2010 he moved to the University of Florida for Ph.D. studies and as a result of his efforts has recently joined with Breathtec Biomedical to propel his own bioanalytical research through the development of revolutionary clinical devices utilizing his background in ion mobility, mass spectrometry, and exhaled breath analysis.